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Summary HPA axis abnormalities
in FM, CFS, and other stress-related
disorders must be placed in a broad
clinical context. We know that inter-
ventions providing symptomatic im-
provement in patients with FM and
CFS can directly or indirectly affect
the HPA axis. These interventions
include exercise, tricyclic anti-de-
presssants, and serotonin reuptake
inhibitors. There is little direct infor-
mation as to how the specific HPA
axis perturbations seen in FM can
be related to the major symptomatic
manifestations of pain, fatigue, sleep
disturbance, and psychological dis-
tress. Since many of these somatic
and psychological symptoms are
present in other syndromes that ex-
hibit HPA axis disturbances, it
seems reasonable to suggest that
there may be some relationship be-
tween basal and dynamic function
of the HPA axis and clinical mani-






sowie anderen Erkrankungen, bei
denen Streßeinflu¨sse eine große
Rolle zu spielen scheinen, mu¨ssen in
einem gro¨ßeren klinischen Kontext
gesehen werden. Wir wissen, daß
therapeutische Interventionen, die
eine symptomatische Besserung bei
Patienten mit FM und CFS bewirken,
direkt oder indirekt Auswirkungen




Hemmer mit ein. Es ist wenig u¨ber
die genauen Beziehungen zwischen
den spezifischen Regula-
tionsänderungen der HPA-Achse bei
FM und den Hauptsymptomen wie
Schmerz, Schwa¨che, Schlaftsto¨run-
gen und psychologischer Streß be-
kannt. Da viele dieser somatischen
und psychologischen Symptome
auch bei anderen Syndromen vor-
kommen, welche Sto¨rungen der
HPA-Achse zeigen, scheint es folge-
richtig anzunehmen, daß zwischen
den klinischen Manifestationen von
FM und CFS Beziehungen zu basa-
len und dynamischen Funktionen der
HPA-Achse bestehen.
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Clinical syndromes characterized by diffuse musculo-
skeletal pains and fatigue precipitated or aggravated by
physical or emotional stressors have a lengthy history
in medical literature (12). However, it was not until re-
cently that efforts to classify patients into more homo-
geneous clinical groups has made it possible to begin
investigation of basic biochemical mechanisms underly-
ing these syndromes. In 1990, the American College of
Rheumatology formalized classification criteria for fi-
romyalgia (FM) based on the presence of widespread
musculoskeletal pain and the presence of specific tender
points (30). Similarly, the Centers for Disease Control
and Prevention proposed a working case definition for
chronic fatigue syndrome (CFS), based on persistent or
relapsing, debilitating fatigue in the absence of an alter-
nate diagnosis explaining the clinical presentation (84,
85). Despite the magnitude of clinical and public health
concerns associated with FM and CFS, little is known
of the underlying pathophysiology of these syndromes.
Analysis of neuroendocrine and circadian architecture
has proven to be one of the most fruitful areas of
resarch into the pathobiology of these disorders. This
manuscript will review the function of the HPA axis
and summarize disturbances of HPA axis function in
FM, CFS, and related disorders.
A Stress Model of FM and CFS
It has been hypothesized that FM and CFS fall into the
spectrum of what might be termed ‘stress-related ill-
nesses’ because of the increase in symptoms associated
with physical or emotional stress. Dysregulation of the
normal stress response can lead to abnormalities in both
physical and behavioral adaptation that may mimic
some of the clinical symptoms of FM. Other conditions
that share substantial symptomatic overlap with FM and
CFS, such as irritable bowel syndrome, chronic head-
aches, irritable bladder syndrome, and temporomandibu-
lar disorders, are also thought to be associated with
stress (8). The HPA axis is generally considered to play
a pivotal role in the coordinated physiological response
to physical and emotional stress.
HPA Axis Physiology
Regulation of the HPA axis involves a complex array
of biochemical events occurring principally among the
hypothalamus, anterior pituitary, and the cortex of the
adrenal gland (Fig. 1) (5). Corticotropin-releasing hor-
mone (CRH) and arginine vasopressing (AVP) are neu-
rohormones with cell bodies in the medial parvocellular
division of the paraventricular nucleus (PVN) of the hy-
pothalamus. CRH is also widely distributed in other, ex-
tra-hypothalamic locations including the limbic system,
cerebral cortex, mid-brain areas, pons, and medulla. Ac-
tivation of the HPA axis results in the release of these
peptides into the hypophyseal portal plexus. Stimulation
of specific receptors for CRH and AVP on the cortico-
troph cells of the anterior pituitary results in the release
of adrenocorticotropic hormone (ACTH) into the sys-
temic circulation, primarily affecting glucocorticoid re-
lease from the adrenal cortex. CRH and AVP act syner-
gistically, with AVP causing a tremendous amplification
of CRH-induced release of ACTH. Indeed, evidence
supports a role for AVP in sustaining the activation of
the HPA axis during chronic stress (11, 21, 25). Com-
plex short and long negative feedback circuits, primar-
ily mediated by specific glucocorticoid receptors, con-
verge to terminate activation of the HPA axis.
In addition to its stress-dependent activation, the HPA
axis exhibits a pronounced spontaneous near 24 h, or cir-
cadian, rhythm. In humans, this circadian rhythm is en-
trained to the light-dark and sleep-wake cycles (10), with
the trough of activity occurring in the evening and early
night and the peak in activity occurring just before wak-
ing. Stress-induced secretion is superimposed on this ba-
sal circadian rhythm. There is evidence that the stress
responsiveness and negative feedback regulation of the
HPA axis varies throughout the day, hence specific altera-
tions in the timing, intensity, and duration of any stressor
may result in widely varying patterns of HPA axis pertur-
bation. It is thought, however, that under normal condi-
tions the HPA axis may be a ‘closed loop’ system, such
that activation of cortisol secretion by stress will result
in a compensatory decrease in circadian drive for cortisol
secretion with maintenance of 24 h integrated cortisol
levels in the ‘normal’ range.
HPA Axis Dysregulation in FM and Related Disorders
It has been proposed that the phenomenological overlap
between FM, CFS, and a variety of ‘stress-related’ so-
matic and psychiatric syndromes reflects the involve-
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Fig. 1 The Hypothalamic-Pituitary-adrenal (HPA) Axis. Corticotro-
pin releasing hormone (CRH), the principal activating hormone, and
arginine vasopressin (AVP), an adjunctive secretagogue, are released
from the paraventricular nucleus of the hypothalamus into the hypo-
physeal portal plexus. Stimulation of specific receptors for CRH and
AVP on the corticotroph cells of the anterior pituitary results in the
release of adrenocorticotropic hormone (ACTH) into the systemic cir-
culation, primarily affecting glucocorticoid release from the adrenal
cortex. Cortisol acts through multiple negative feedback mechanisms
to inhibit HPA axis activation. Cortisol also has important physiologic
functions that allow adaptation to stress
ment of a shared final pathway, the HPA axis, which
may be perturbed as the result of a disparate variety of
antecedent events (7). The earliest studies of stress-re-
sponse systems in human disease states led to the obser-
vation that patients with major depression demonstrated
a characteristic disruption of the normal circadian rhyth-
micity of the pituitary-adrenal axis involving an eleva-
tion of adrenal glucocorticoid output, usually seen as an
earlier onset of the morning surge of the axis, in con-
junction with enhanced cortisol secretion in the late
afternoon (24). Aberrant feedback regulation of the axis
was suggested by studies employing the synthetic glu-
cocorticoid, dexamethasone (4). A model of HPA axis
dysregulation which suggests an excessive central re-
lease of CRH in some cases of major depression was
developed.
The initial investigations of the neuroendocrine cor-
relates of depression largely concerned the more classi-
cal, melancholic form of depression, characterized by
increasing agitation, loss of sleep, loss of interest in all
activities, persistent suicidal thoughts, and reduced ap-
petite and libido. In recent years, however, it has be-
come increasingly apparent that depression is a hetero-
geneous condition from both a psychological and a
physiological perspective. Forms of depressive illness
dominated by reduced energy, a reactive mood, and a
reversal of the typical pattern of vegetative features
seen in classical depression have been described (5).
These depressive subtypes are of particular interest be-
cause of their overlap with the symptoms of FM and
CFS. Recent evidence suggests a pattern of HPA func-
tion in some of these syndromes reflecting inappropri-
ately normal or frankly reduced activation of the axis
(17–19, 23, 29). It has been hypothesized that one of
the principal features of the HPA axis disturbance in
these conditions may be functionaldeficit in the release
of hypothalamic CRH. This is of interest since CRH
serves not only as a principal stimulus to the HPA axis,
but also because it is a behaviorally active neurohor-
mone whose central administration to animals and non-
human primates induces signs of physiological and be-
havioral arousal, including activation of the sympathetic
nervous system (3), hyper-responsiveness to sensory
stimuli (27), and increased locomotion (26). It must be
noted, however, that posttraumatic stress disorder
(PTSD) is also characterized by low levels of cortisol
that were shown to be due to enhanced glucocorticoid
negative feedback rather that low levels of CRH (32).
The symptomatic overlap of FM and CFS with some
forms of depression, and the increased lifetime inci-
dence of psychiatric conditions, provoked further inter-
est in examining the specific neuroendocrine character-
istics of patient with FM and CFS (Table 1). Poteliak-
hoff reported in 1981 that subjects with both acute and
chronic fatigue states showed reductions in plasma cor-
tisol compared to non-fatigued individuals, along with
altered circadian variation in capillary resistance and
eosinophil counts (22). These results are of interest
since they suggest that even quite mild decrements in
circulating glucocorticoids may be associated with mea-
urable physiologic changes. In a report of benign
myalgic encephalomyelitis (an illness essentially identi-
cal to CFS), only 1 of 16 subjects showed evidence of
glucocorticoid non-suppression after dexamethasone
(28). Demitrack and co-workers, reported reduced urine
free cortisol in association with inappropirately low
concentrations of CRH and ACTH in the cerebrospinal
fluid, low evening plasma cortisol, elevated evening
plasma ACTH with blunted response to exogenous ad-
ministration of ovine CRH, and altered responsiveness
f the adrenal cortex to graded doses of ACTH (13).
Bearn and colleagues reported that patients with CFS
did not differ form controls in response to insulin chal-
lenge but displayed exaggerated ACTH, but not corti-
sol, response to d-fenfluramine, which causes pre-syn-
aptic release of serotonin (2). In a related study, this
group compared the response to d-fenfluramine in pa-
t ents with CFS and major depressive disorder, demon-
strating a reduced cortisol profile relative to depressed
patients while healthy controls fell between the two pa-
tient groups (6). In contrast, Yatham and colleagues re-
ported no difference in the cortisol response between
CFS and normal subjects after administration of d/l-fen-
fluramine (31).
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Table 1 Comparison of HPA Axis Parameters in FM and CFS
FM CFS
Brain – Diurnal Rhythm Blunted –
– CSF CRH – Reduced
– Plasma AVP
(Magnocellular)


















Pituitary – Basal ACTH Normal Elevated PM
– CRH Challenge Exaggerated ACTH Blunted ACTH
Adrenal – Basal Cortisol Normal AM,
Elevated PM
Decreased PM
– 24-h Urine Free
Cortisol
Decreased Decreased
– ACTH Challenge Normal : Sensitivity,
; Capacity
– CRH Challenge Blunted Cortisol Normal
In contrast to CFS, up to 35% of patients with FM
showed abnormal suppression after dexamethasone (14,
16). McCain and Tilbe reported that patients with FM
had reduced 24-hour urine free cortisol excretion,but a
loss of the circadian fluctuation of glucocorticoid levels
with elevated levels during the circadian nadir (20).
Griep and colleagues reported exaggerated ACTH, but
blunted cortisol response to exogenous administration
of human CRH and to insulin-induced hypoglycemia
(15). In our own studies, we also found a loss of circa-
dian fluctuation of plasma cortisol in patients with FM
due to elevated levels, with reduced overall 24-hour
urine free cortisol excretion that could not be explained
by excess cortisol binding globulin (9). On provocative
challenge with ovine CRH, there was a trend towards
increased ACTH, but blunted cortisol respone to exo-
genous CRH, similar to the findings of Griep (9). In a
paradigm employing a different kind of hypoglycemic
challenge where the rate of decline in blood glucose is
carefully titrated or clamped, Adler and co-workers re-
ported reudced ACTH secretion with a cortisol response
no different from control subjects (1). It can be seen
from these data that the pattern of HPA axis response
appears to diverge between these conditions, with exag-
gerated activity (physiological hyperarousal) in FM and
blunted activity in CFS.
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